- Home
- DIAX vs CTMX Comparison
DIAX vs CTMX Comparison
Compare DIAX & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIAX
- CTMX
- Stock Information
- Founded
- DIAX 2005
- CTMX 2008
- Country
- DIAX United States
- CTMX United States
- Employees
- DIAX N/A
- CTMX N/A
- Industry
- DIAX Finance Companies
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- DIAX Finance
- CTMX Health Care
- Exchange
- DIAX Nasdaq
- CTMX Nasdaq
- Market Cap
- DIAX 516.0M
- CTMX 444.3M
- IPO Year
- DIAX N/A
- CTMX 2015
- Fundamental
- Price
- DIAX $13.64
- CTMX $2.33
- Analyst Decision
- DIAX
- CTMX Strong Buy
- Analyst Count
- DIAX 0
- CTMX 2
- Target Price
- DIAX N/A
- CTMX $5.00
- AVG Volume (30 Days)
- DIAX 96.6K
- CTMX 3.3M
- Earning Date
- DIAX 01-01-0001
- CTMX 08-07-2025
- Dividend Yield
- DIAX 7.93%
- CTMX N/A
- EPS Growth
- DIAX N/A
- CTMX 128.27
- EPS
- DIAX N/A
- CTMX 0.49
- Revenue
- DIAX N/A
- CTMX $147,557,000.00
- Revenue This Year
- DIAX N/A
- CTMX N/A
- Revenue Next Year
- DIAX N/A
- CTMX N/A
- P/E Ratio
- DIAX N/A
- CTMX $4.78
- Revenue Growth
- DIAX N/A
- CTMX 23.81
- 52 Week Low
- DIAX $12.80
- CTMX $0.40
- 52 Week High
- DIAX $15.12
- CTMX $3.10
- Technical
- Relative Strength Index (RSI)
- DIAX 34.64
- CTMX 49.57
- Support Level
- DIAX $13.64
- CTMX $2.08
- Resistance Level
- DIAX $13.92
- CTMX $3.10
- Average True Range (ATR)
- DIAX 0.12
- CTMX 0.26
- MACD
- DIAX -0.06
- CTMX -0.11
- Stochastic Oscillator
- DIAX 1.56
- CTMX 15.20
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.